Literature DB >> 28280116

Diagnosis and Management of Type 2 Diabetic Kidney Disease.

Simit M Doshi1, Allon N Friedman2.   

Abstract

Type 2 diabetic kidney disease (DKD) is the most common cause of CKD and ESRD worldwide, and carries with it enormous human and societal costs. The goal of this review is to provide an update on the diagnosis and management of DKD based on a comprehensive review of the medical literature. Topics addressed include the evolving presentation of DKD, clinical differentiation of DKD from non-DKD, a state-of-the-art evaluation of current treatment strategies, and promising emerging treatments. It is expected that the review will help clinicians to diagnose and manage patients with DKD.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  Chronic; Costs and Cost Analysis; Diabetic Nephropathies; Disease Management Disease Management; Goals; Humans; Kidney Failure; Publications; Renal Insufficiency

Mesh：

Substances：

Year:  2017        PMID： 28280116      PMCID： PMC5544517          DOI： 10.2215/CJN.11111016

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


  44 in total

1.  Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.

Authors:  Faramarz Ismail-Beigi; Timothy E Craven; Patrick J O'Connor; Diane Karl; Jorge Calles-Escandon; Irene Hramiak; Saul Genuth; William C Cushman; Hertzel C Gerstein; Jeffrey L Probstfield; Lois Katz; Ulrich Schubart
Journal:  Kidney Int       Date:  2011-12-14       Impact factor: 10.612

2.  Clinical significance of nonalbuminuric renal impairment in type 2 diabetes.

Authors:  Giuseppe Penno; Anna Solini; Enzo Bonora; Cecilia Fondelli; Emanuela Orsi; Gianpaolo Zerbini; Roberto Trevisan; Monica Vedovato; Gabriella Gruden; Franco Cavalot; Mauro Cignarelli; Luigi Laviola; Susanna Morano; Antonio Nicolucci; Giuseppe Pugliese
Journal:  J Hypertens       Date:  2011-09       Impact factor: 4.844

3.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

4.  Clinical features of non-diabetic renal diseases in patients with type 2 diabetes.

Authors:  Atsuhito Tone; Kenichi Shikata; Mitsuhiro Matsuda; Hitomi Usui; Shinichi Okada; Daisuke Ogawa; Jun Wada; Hirofumi Makino
Journal:  Diabetes Res Clin Pract       Date:  2005-03-23       Impact factor: 5.602

5.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

6.  Renal outcomes in patients with type 2 diabetes with or without coexisting non-diabetic renal disease.

Authors:  Tae Ik Chang; Jung Tak Park; Jwa-kyung Kim; Seung Jun Kim; Hyung Jung Oh; Dong Eun Yoo; Seung Hyeok Han; Tae-Hyun Yoo; Shin-Wook Kang
Journal:  Diabetes Res Clin Pract       Date:  2011-02-12       Impact factor: 5.602

7.  Predictive factors for non-diabetic nephropathy in diabetic patients. The utility of renal biopsy.

Authors:  Sheila Bermejo; María José Soler; Javier Gimeno; Clara Barrios; Eva Rodríguez; Sergi Mojal; Julio Pascual
Journal:  Nefrologia       Date:  2016-08-11       Impact factor: 2.033

8.  Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade.

Authors:  Paul M Palevsky; Jane H Zhang; Stephen L Seliger; Nicholas Emanuele; Linda F Fried
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-27       Impact factor: 8.237

9.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

10.  Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.

Authors:  Vlado Perkovic; Hiddo Lambers Heerspink; John Chalmers; Mark Woodward; Min Jun; Qiang Li; Stephen MacMahon; Mark E Cooper; Pavel Hamet; Michel Marre; Carl Erik Mogensen; Neil Poulter; Giuseppe Mancia; Alan Cass; Anushka Patel; Sophia Zoungas
Journal:  Kidney Int       Date:  2013-01-09       Impact factor: 10.612
View more
  75 in total

1.  Deteriorated functional and structural brain networks and normally appearing functional-structural coupling in diabetic kidney disease: a graph theory-based magnetic resonance imaging study.

Authors:  Yun Fei Wang; Ping Gu; Jiong Zhang; Rongfeng Qi; Michael de Veer; Gang Zheng; Qiang Xu; Ya Liu; Guang Ming Lu; Long Jiang Zhang
Journal:  Eur Radiol       Date:  2019-04-01       Impact factor: 5.315

2.  Chronic kidney disease in low-middle income populations: a call to action for screening and prevention.

Authors:  Anna Paini; Massimo Salvetti; Silvio Caligaris; Francesco Castelli; Maria Lorenza Muiesan
Journal:  Intern Emerg Med       Date:  2018-12-06       Impact factor: 3.397

3.  The effect of hemodialysis on individual retinal layer thickness.

Authors:  Idit Maharshak; Idan Hecht; Lihi Mankuta; Asaf Achiron; Oriel Spierer; Zvia Burgansky; Asaf Bar; Aliza Grossbard; Anna Katkov; Relu Cernes; Leonid Feldman
Journal:  Int Ophthalmol       Date:  2021-01-03       Impact factor: 2.031

4.  Histological Evidence of Diabetic Kidney Disease Precede Clinical Diagnosis.

Authors:  Giorgia Comai; Deborah Malvi; Andrea Angeletti; Francesco Vasuri; Sabrina Valente; Francesca Ambrosi; Irene Capelli; Matteo Ravaioli; Gianandrea Pasquinelli; Antonietta D'Errico; Alessia Fornoni; Gaetano La Manna
Journal:  Am J Nephrol       Date:  2019-06-05       Impact factor: 3.754

5.  High glucose reduces megalin-mediated albumin endocytosis in renal proximal tubule cells through protein kinase B O-GlcNAcylation.

Authors:  Diogo de Barros Peruchetti; Rodrigo Pacheco Silva-Aguiar; Gabriela Marques Siqueira; Wagner Barbosa Dias; Celso Caruso-Neves
Journal:  J Biol Chem       Date:  2018-06-05       Impact factor: 5.157

Review 6.  Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.

Authors:  Emily J North; Jonathan D Newman
Journal:  Curr Opin Cardiol       Date:  2019-11       Impact factor: 2.161

7.  Higher Serum Asprosin Level is Associated with Urinary Albumin Excretion and Renal Function in Type 2 Diabetes.

Authors:  Xia Deng; Li Zhao; Chang Guo; Ling Yang; Dong Wang; Yanyan Li; Hong Xia; Chenxi Wang; Zhensheng Cai; Lian Li; Zhicong Zhao; Guoyue Yuan
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-13       Impact factor: 3.168

8.  Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease.

Authors:  Shohei Mitsui; Yuji Oe; Akiyo Sekimoto; Emiko Sato; Yamato Hashizume; Shu Yamakage; Satoshi Kumakura; Hiroshi Sato; Sadayoshi Ito; Nobuyuki Takahashi
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-23

9.  COL4A3 Gene Variants and Diabetic Kidney Disease in MODY.

Authors:  Yiting Wang; Junlin Zhang; Yingwang Zhao; Shanshan Wang; Jie Zhang; Qianqian Han; Rui Zhang; Ruikun Guo; Hanyu Li; Li Li; Tingli Wang; Xi Tang; Changzheng He; Geer Teng; Weiyue Gu; Fang Liu
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-16       Impact factor: 8.237

10.  Primary Care Providers' Acceptance of Pharmacists' Recommendations to Support Optimal Medication Management for Patients with Diabetic Kidney Disease.

Authors:  Leah L Zullig; Shelley A Jazowski; Clemontina A Davenport; Clarissa J Diamantidis; Megan M Oakes; Sejal Patel; Jivan Moaddeb; Hayden B Bosworth
Journal:  J Gen Intern Med       Date:  2019-10-28       Impact factor: 5.128
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.